Montelukast Stada

Montelukast, the active ingredient in Montelukast Stada, is a leukotriene receptor antagonist presented as an oral tablet for systemic use. It is used to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children as part of maintenance therapy.

GNH USA supplies Montelukast Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets and providing reliable logistics for timely delivery.

Montelukast acts on leukotriene pathways to control inflammatory airway conditions. - Asthma (maintenance therapy): improves control of chronic asthma, reduces symptoms and risk of exacerbations in adults and children. - Allergic rhinitis: relieves nasal congestion, sneezing, itching and rhinorrhea associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents airway narrowing and breathing difficulty triggered by physical exertion.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often transient. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: occasional irritation of the throat. - Nausea: feeling of sickness without vomiting. - Dizziness: light‑headed sensation. - Fatigue: unusual tiredness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Mood changes: depression, anxiety, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Stevens‑Johnson syndrome: severe skin reaction. - Anaphylactic shock: life‑threatening systemic allergic response.

Before using Montelukast, consider the following safety measures. - Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: unknown; evaluate potential risks to the infant. - Pediatric use: approved for children ≥6 months; follow prescriber guidance. - Drug interactions: review concomitant medications for potential interactions. - Renal/hepatic impairment: monitor closely if severe organ dysfunction is present. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Montelukast may interact with several medicines; assess the clinical relevance.

Major Interactions (Avoid): - Ritonavir: may increase montelukast plasma concentrations. - Phenobarbital: may reduce montelukast effectiveness. - Carbamazepine: may lower plasma levels of montelukast.

Moderate Interactions (Monitor Closely): - Fluconazole: may modestly raise montelukast levels. - Warfarin: monitor INR as montelukast could affect anticoagulant metabolism.